ReviewDiabetology & metabolic syndrome2026
Duodenal mucosal intervention in the management of MASLD and type 2 diabetes.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) is rooted in the gut-liver axis dysfunction. To enhance glycemic control and liver fat level, new duodenal mucosal ablation procedures, such as duodenal mucosal resurfacing (DMR), recellularization via electroporation therapy (ReCET), and photodynamic therapy, seek to reset duodenal signaling in a less invasive manner.
methodsA systematic review (2016-2024) was carried out. Both observational studies and randomized controlled trials (RCTs) assessing duodenal mucosal treatments in adult patients with T2DM and/or MASLD were included. Changes in liver fat, insulin resistance, fasting plasma glucose (FPG), HbA1c, and safety profiles were key outcomes of interest.
resultsThe sham-controlled REVITA-2 RCT showed that DMR is safe and produces clinically significant metabolic benefits: at 12 weeks, liver fat (MRI-PDFF) decreased by 5.4% versus 2.2% (p = 0.035) and HbA1c reduced by 6.6 mmol/mol vesus 3.3 mmol/mol in the sham group(p = 0.033) among European participants. Without significant safety concerns, duodenal mucosal ablation procedures were found to lower HbA1c, FPG, and liver fat in 15 studies (n = 317), including seven DMR and two ReCET reports. These techniques also lead to insulin cessation in 86% of patients.
conclusionDuodenal mucosal treatments, in particular DMR, appear to be viable minimally invasive approaches to treat the dual metabolic loads of T2DM and MASLD. Although long-term studies with histologic outcomes in MASLD are warranted to validate the efficacy and refine patient selection criteria, these methods seem safe and beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.